Skip to content

Managing Pain and Cognitions in Older Adults With Early Cognitive Decline and Chronic Pain

Addressing the Chronic Pain-Early Cognitive Decline Comorbidity Among Older Adults; The Active Brains Study

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05373745
Enrollment
267
Registered
2022-05-13
Start date
2022-06-20
Completion date
2026-06-01
Last updated
2026-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Pain, Mild Cognitive Impairment, Older Adults, Physical Activity

Keywords

Chronic Pain, Mild Cognitive Impairment, Older Adults, Physical Activity, Memory Related Problems, Early Cognitive Decline

Brief summary

The investigators aim to conduct a fully powered randomized controlled trial to compare the efficacy of two symptom management programs for older adults with early cognitive decline (either self-reported or confirmed by testing) and chronic pain, Active Brains 1 and Active Brains 2. The investigators will assess how each program may help in improving multimodal physical, cognitive and emotional function. The investigators will also assess whether improvements in outcomes from the two programs are maintained through 6-months follow-up. The investigators will also explore whether improvements in outcomes are mediated by nonadaptive pain reactions, adaptive coping, social factors and compensatory strategies and modified by demographic and clinical predictors. Both programs will be delivered virtually (Zoom).

Detailed description

The investigators aim to conduct a fully powered randomized controlled trial to establish efficacy of two symptom management programs for older adults with early cognitive decline (either self-reported or confirmed by testing) and chronic pain, Active Brains 1 and Active Brains 2. The investigators will assess how the two programs may help in improving multimodal physical, cognitive and emotional function. The investigators will also assess whether improvements in outcomes are maintained through 6-months follow-up. The investigators will also explore whether improvements in outcomes are mediated by nonadaptive pain reactions, adaptive coping, social factors and compensatory strategies and modified by demographic and clinical predictors, and type of early cognitive decline. Both programs will be delivered virtually (Zoom). Each group meets for eight, 90 minutes sessions over the secure Zoom platform. Each group has 5-8 participants. Participants receive a treatment manual. There are 3 assessment points: baseline, post program and 6-month follow-up. Assessments involve self-report questionnaires, a walk test and a neuropsychological evaluation.

Interventions

BEHAVIORALActive Brains 1

Active Brains 1 uses a multimodal approach to introduce and reinforce new skills, including didactics, in-session activities, discussions and weekly practice assignments (homework). The Active Brains sessions teach skills and strategies to manage early cognitive concerns and chronic pain. The format is an 8-week program with weekly meetings and a focus on relaxation response strategies, cognitive behavioral training, positive psychology and mind-body interactions. Active Brains 1 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

BEHAVIORALActive Brains 2

This active comparison condition controls for the effect of time spent, group member support/feedback and interventionist support/feedback. Active Brains 2 addresses population-specific challenges of chronic pain and early cognitive decline symptoms. Participants also receive lifestyle education consistent from public health recommendations and standards for health promotion (e.g., "Sleep", "Nutrition", "Healthy Weight" and "Medical appointments". The Active Brains 2 program consists on 8 group sessions (each session is 90 minutes) that occur concurrently with the active intervention condition. The Active Brains 2 is conducted in the same format as Active Brains 1, but participants are not taught the mind-body, walking or cognitive-behavioral skills. Active Brains 2 uses a wrist-worn digital monitoring device (ActiGraph) for recording of physical activity.

Sponsors

Massachusetts General Hospital
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
60 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Male and female outpatients, age 60 years or older * Have nonmalignant chronic pain for more than 3 months * Reports early cognitive decline (subjective or objective) * Telephone Interview for Cognitive Status-30 score greater than or equal to 17 * Functional Activities Questionnaire score less than 9 * Able to perform a 6-minute walk test at an accelerated pace * English fluency/literacy * Willingness and ability to participate and use an ActiGraph watch and smartphone app to view and sync the step count and sleep data * Free of concurrent psychotropic or pain medication for at least 2 weeks prior to initiation of treatment, OR stable on current psychotropic or pain medication for a minimum of 6 weeks and willing to maintain a stable dose * Cleared by a medical doctor for study participation and no self-reported concerns about physical functioning on the revised Physical Activity Readiness Questionnaire (PAR-Q; score 0)

Exclusion criteria

* Diagnosed with dementia or neurodegenerative disease * Diagnosed with medical illness expected to worsen in the next 6 months * Diagnosed with serious untreated mental illness (i.e., schizophrenia) or untreated substance use disorder * Current suicidal ideation reported on self-report * Engaging in regular mindfulness practice \> 45 min/week or has completed a course of cognitive behavioral therapy in the past 3 months * Regular use of a digital-monitoring device * Engagement in regular intensive physical exercise for \>30 minute daily

Design outcomes

Primary

MeasureTime frameDescription
Change in PROMIS Physical Function0 Weeks, 8 Weeks, 6 MonthsChange in rate of a participant's capability rather than performance of physical activities, with items ranging from 1-4. Higher T scores indicate greater physical function.
Change in Step Count via the ActiGraph wGT3X-BTLE Accelerometer0 Weeks, 8 Weeks, 6 MonthsMeasures the change in steps during the 7 days preceding baseline assessment, throughout the intervention period, and 7 days preceding 6-month follow-up.
Change in six-minute walk test (6MWT)0 Weeks, 8 Weeks, 6 MonthsAssesses distance walked in 6 minutes.

Secondary

MeasureTime frameDescription
Repeatable Battery for the Assessment of Neuropsychological Status (RBANS)0 Weeks, 8 Weeks, 6 MonthsA comprehensive test of five cognitive domains (immediate memory, visuospatial/constructional, language, attention, and delayed memory) and global cognition.
Everyday Cognition Scale (eCog-12)0 Weeks, 8 Weeks, 6 MonthsRate of participant's cognitively mediated functional abilities, with items ranging from 1-5. Scores are calculated by averaging the 12 items, and range from 1-5, with higher scores indicating greater cognitive decline.
PROMIS Depression0 Weeks, 8 Weeks, 6 MonthsRate of a participant's negative mood, social cognition and views of self, with items ranging from 1-5. Higher T scores indicate higher levels of depression.
PROMIS Anxiety0 Weeks, 8 Weeks, 6 MonthsRate of a participant's fear, anxious, hyperarousal and somatic symptoms pertaining to arousal, with items ranging from 1-5. Higher T scores indicate higher levels of anxiety.
Numerical Rating Scale0 Weeks, 8 Weeks, 6 MonthsRate of a participant's pain at rest and with activity using a Likert scale with 0 being no pain and 10 being worst possible pain.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORAna-Maria Vranceanu, PhD

Massachusetts General Hospital

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Jun 13, 2026